Cargando…
Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
Trifluridine/tipiracil (FTD/TPI) is an oral anticancer agent used as a third- or later-line treatment for patients with metastatic gastric cancer/gastroesophageal junction cancer (mGC/GEJC). The C-reactive protein-to-serum albumin ratio (CAR) is an inflammation-based prognostic marker in gastric can...
Autores principales: | Hashimoto, Itaru, Kano, Kazuki, Onuma, Shizune, Suematsu, Hideaki, Nagasawa, Shinsuke, Kanematsu, Kyohei, Furusawa, Kyoko, Hamaguchi, Tomomi, Watanabe, Mamoru, Hayashi, Kei, Furuta, Mitsuhiro, Inokuchi, Yasuhiro, Machida, Nozomu, Aoyama, Toru, Yamada, Takanobu, Rino, Yasushi, Ogata, Takashi, Oshima, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303086/ https://www.ncbi.nlm.nih.gov/pubmed/37373912 http://dx.doi.org/10.3390/jpm13060923 |
Ejemplares similares
-
Clinical Effects of the Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients with Gastric Cancer after Gastrectomy
por: Onuma, Shizune, et al.
Publicado: (2023) -
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021) -
Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021) -
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019) -
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)